Table 5.
Baseline Characteristics of Patients in the HARVEST Registry and the Other Acute Heart Failure Population
| Variable | HARVEST, n=2143 | Validation Cohort, n=175 | P Value |
|---|---|---|---|
| Age, y | 76.7±12.3 | 69.9±15.4 | <0.01 |
| Male sex, n (%) | 1449 (67.6) | 135 (77.1) | <0.01 |
| LVEF, % | 54.9±18.8 | 39.2±15.2 | <0.01 |
| HFrEF, n (%) | 681 (31.8) | 118 (67.4) | <0.01 |
| Comorbidities, n (%) | |||
| Hypertension | 1287 (60.1) | 130 (74.3) | <0.01 |
| Diabetes mellitus | 816 (38.1) | 88 (50.3) | <0.01 |
| Coronary artery disease | 645 (30.1) | 102 (58.3) | <0.01 |
| Atrial fibrillation | 843 (39.3) | 47 (26.9) | <0.01 |
| Hematology and biochemistry | |||
| Hemoglobin, g/dL | 11.8±2.2 | 11.8±2.3 | 0.85 |
| Creatinine, mg/dL | 1.9±1.4 | 1.79±0.96 | 0.20 |
| eGFR, mL/min per 1.73 m2 | 52.0±29.4 | 50.6±27.1 | 0.69 |
| Sodium, mmol/L | 138.7±4.8 | 138.5±4.4 | 0.31 |
| Uric acid, mg/dL | 8.6±3.0 | 9.1±8.7 | 0.86 |
| Total cholesterol, mg/dL | 155.4±42.7 | 156.9±37.6 | 0.26 |
| LDL cholesterol, mg/dL | 94.0±34.4 | 100.3±32.4 | <0.01 |
| NT‐proBNP, pg/mLa | 3.8±0.6 (n=767) | 7.7±1.6 (n=89) | <0.01 |
| Pharmacological therapy, n (%) | |||
| RAS inhibitors | 1789 (83.5) | 125 (71.4) | <0.01 |
| β‐Blockers | 1356 (63.3) | 105 (60.0) | 0.39 |
| MRAs | 1222 (57.0) | 99 (56.6) | 0.91 |
| Statin | 850 (39.7) | 49 (28.0) | <0.01 |
eGFR indicates estimated glomerular filtration rate; HARVEST, heart failure registry of Taipei Veterans General Hospital; HFrEF, heart failure with reduced left ventricular ejection fraction; LDL, low‐density lipoprotein; LVEF, left ventricular ejection fraction; MRAs, mineralocorticoid antagonists; NT‐proBNP, N‐terminal prohormone brain natriuretic peptide; RAS, renin‐angiotensin system.
a
NT‐proBNP were log‐transformed.